CAPITOL COUNSEL LLC for GENENTECH
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
340B Program issues and patient access to pharmaceuticals. Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2). Legislative issues associated with patient access to treatment, including the CMMI Most Favored Nation demonstration; and step therapy, including related provisions in S. 464/H.R. 2163, the Safe Step Act. Medical Supply Chain, including issues related to a new rating system; targeted action to support the diversification of certain supplies; additional funding to the Strategic National Stockpile (SNS) and more diverse stockpile; increasing flexibility for supply chains; enhanced FDA reporting and risk mitigation plans for certain medicines; and improved coordination and expansion of mutual reliance agreements, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CAITLIN CANTER | — |
| AARON COHEN | — |
| JOSEPH EANNELLO | — |
| SHANNON FINLEY | — |
| SARA FRANKO | — |
| MARTIN B. GOLD | — |
| LUKE HATZIS | — |
| DENISE HENRY MORRISEY | — |
| ANN JABLON | — |
Trade (domestic/foreign) TRD
Medical Supply Chain, including issues related to strengthening trade relationships through negotiations with the United States Trade Representative (USTR) and US partners to develop appropriate sources to help secure the US supply chain, along with coordination with trade partners to maintain free movement of goods.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CAITLIN CANTER | — |
Medicare/Medicaid MMM
Implementation issues affecting patient access to Medicare covered pharmaceuticals and reimbursement adequacy, Medicare Parts B and D benefit parameters, coverage, and reimbursement requirements; use of step therapy in Medicare and health insurance coverage; including related provisions in H.R. 3, the Lower Drug Costs Now Act, H.R. 19, the Lower Costs, More Cures Act, and S. 464/H.R. 2163, the Safe Step Act; and antibiotic development incentives, including related provisions in H.R. 4172, to encourage the development and use of certain antimicrobial drugs and H.R. 3932, to establish a program to develop antimicrobial innovations. Coronavirus response efforts, including implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2). Enhance Center for Medicare & Medicaid Innovation quality initiatives and patient access to Medicare Part B covered drugs, including the Most Favored Nation demonstration.
Foreign entity interest: Foreign parent affected by policies affecting U.S. subsidiary.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CAITLIN CANTER | — |
| AARON COHEN | — |
| SHANNON FINLEY | — |
| SARA FRANKO | — |
| MARTIN B. GOLD | — |
| LUKE HATZIS | — |
| DENISE HENRY MORRISEY | — |
| ANN JABLON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.